Article

RhuFab V2 safety and benefits maintained with continued dosing

Ft. Lauderdale-New results from the ongoing, Phase Ib/II open-label,randomized controlled trial of rhuFab V2 for the treatment of exudativeAMD show that a second course of treatment with up to four injection iswell-tolerated and provides ongoing biologic activity, reported JeffreyS. Heier, MD.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
1 expert is featured in this series.
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Related Content
New research links retinal imaging and deep learning to improved schizophrenia detection
January 11th 2025

New research links retinal imaging and deep learning to improved schizophrenia detection

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

FDA accepts revised supplemental New Drug Application for IZERVAY
January 11th 2025

FDA accepts revised supplemental New Drug Application for IZERVAY

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Heidelberg Engineering announces FDA clearance for ANTERION Epithelial Thickness Module, Ectasia View
January 9th 2025

Heidelberg Engineering announces FDA clearance for ANTERION Epithelial Thickness Module, Ectasia View

FDA grants rare pediatric disease designation for retinitis pigmentosa gene therapy candidate VG901 from ViGeneron
January 9th 2025

FDA grants rare pediatric disease designation for retinitis pigmentosa gene therapy candidate VG901 from ViGeneron

© 2025 MJH Life Sciences

All rights reserved.